<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neurosense Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd</link>
<description>Latest news and press releases for Neurosense Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 13:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neurosense-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a35278dffbe2df10a258.webp</url>
<title>Neurosense Therapeutics Ltd</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd</link>
</image>
<item>
<title>NeuroSense Granted Brazilian Patent Covering PrimeC Composition</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-granted-brazilian-patent-covering-primec-composition</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-granted-brazilian-patent-covering-primec-composition</guid>
<pubDate>Mon, 06 Apr 2026 13:20:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib."</description>
</item>
<item>
<title>NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-announces-receipt-of-nasdaq-notifications-regarding-minimum-bid-price-and-market-value-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-announces-receipt-of-nasdaq-notifications-regarding-minimum-bid-price-and-market-value-requirements</guid>
<pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
<description>Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026</description>
</item>
<item>
<title>NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-reports-year-end-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-reports-year-end-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 31 Mar 2026 13:20:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2025 and provided a business update.</description>
</item>
<item>
<title>NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-advances-toward-key-regulatory-milestones-with-strengthened-data-package-and-near-term-alzheimers-readout</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-advances-toward-key-regulatory-milestones-with-strengthened-data-package-and-near-term-alzheimers-readout</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company</description>
</item>
<item>
<title>/C O R R E C T I O N -- NeuroSense/</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/c-o-r-r-e-c-t-i-o-n-neurosense</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/c-o-r-r-e-c-t-i-o-n-neurosense</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>In the news release, PrimeC New Data to Be Presented at AD/PD™ 2026 Conference, issued 18-Mar-2026 by NeuroSense over PR Newswire, we are advised by the</description>
</item>
<item>
<title>JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/jama-neurology-publishes-results-from-paradigm-phase-2b-trial-of-primec-in-als-demonstrating-meaningful-clinical-outcomes-and-biological-activity</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/jama-neurology-publishes-results-from-paradigm-phase-2b-trial-of-primec-in-als-demonstrating-meaningful-clinical-outcomes-and-biological-activity</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM</description>
</item>
<item>
<title>PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/primec-long-term-survival-data-to-be-presented-at-a-leading-als-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/primec-long-term-survival-data-to-be-presented-at-a-leading-als-scientific-conference</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company</description>
</item>
<item>
<title>NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-announces-statistically-significant-65percent-reduction-in-risk-of-death-and-greater-than-14-month-median-survival-benefit-with-primec-in-als</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-announces-statistically-significant-65percent-reduction-in-risk-of-death-and-greater-than-14-month-median-survival-benefit-with-primec-in-als</guid>
<pubDate>Wed, 18 Feb 2026 14:05:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</description>
</item>
<item>
<title>NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-expands-global-ip-protection-142000170</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-expands-global-ip-protection-142000170</guid>
<pubDate>Mon, 09 Feb 2026 14:20:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled "Compositions Comprising Ciprofloxacin and Celecoxib," representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.</description>
</item>
<item>
<title>NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-granted-u-patent-treatment-133000879</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-granted-u-patent-treatment-133000879</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,527,768, entitled "Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases."</description>
</item>
<item>
<title>World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/world-renowned-alzheimers-expert-prof-134500556</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/world-renowned-alzheimers-expert-prof-134500556</guid>
<pubDate>Thu, 08 Jan 2026 13:45:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translatio</description>
</item>
<item>
<title>NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-confirms-favorable-safety-tolerability-140000138</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-confirms-favorable-safety-tolerability-140000138</guid>
<pubDate>Mon, 22 Dec 2025 14:00:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer's disease.</description>
</item>
<item>
<title>NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-hold-pre-nds-meeting-123000084</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-hold-pre-nds-meeting-123000084</guid>
<pubDate>Thu, 04 Dec 2025 12:30:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis (ALS).</description>
</item>
<item>
<title>NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-receives-fda-clearance-initiate-145600572</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-receives-fda-clearance-initiate-145600572</guid>
<pubDate>Mon, 24 Nov 2025 14:56:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial for the evaluation of its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis</description>
</item>
<item>
<title>NeuroSense to Host Investor Webinar on December 8, 2025</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-host-investor-webinar-december-141500863</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-host-investor-webinar-december-141500863</guid>
<pubDate>Mon, 03 Nov 2025 14:15:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it will host an investor update meeting on December 8, 2025 at 8:30 a.m. Eastern Time.</description>
</item>
<item>
<title>NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-primec-produces-statistically-significant-130000161</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-primec-produces-statistically-significant-130000161</guid>
<pubDate>Mon, 06 Oct 2025 13:00:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive findings based on plasma samples from its Phase-2b PARADIGM study. These results indicate that PrimeC produced robust, statistically significant reductions in multiple microRNAs that are consistently implicated in Alzheimer's disease pathology - changes that reflect reduction of neuroinflammatory an</description>
</item>
<item>
<title>NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosenses-drug-candidate-shows-early-183000281</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosenses-drug-candidate-shows-early-183000281</guid>
<pubDate>Wed, 10 Sep 2025 18:30:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial evaluating PrimeC for Alzheimer's disease (AD).</description>
</item>
<item>
<title>NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-announces-500-000-124900248</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-therapeutics-announces-500-000-124900248</guid>
<pubDate>Thu, 04 Sep 2025 12:49:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares.</description>
</item>
<item>
<title>NeuroSense Provides Business Update and Progress for the First Half of 2025</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-provides-business-progress-first-130000892</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/neurosense-provides-business-progress-first-130000892</guid>
<pubDate>Fri, 01 Aug 2025 13:00:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and financial results of the first half of 2025.</description>
</item>
<item>
<title>Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community</title>
<link>https://6ix.com/company/neurosense-therapeutics-ltd/news/award-winning-broadway-television-film-124200207</link>
<guid isPermaLink="true">https://6ix.com/company/neurosense-therapeutics-ltd/news/award-winning-broadway-television-film-124200207</guid>
<pubDate>Tue, 22 Jul 2025 12:42:00 GMT</pubDate>
<description>NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, updates today that in a live broadcast, NeuroSense CEO Alon Ben-Noon will join Aaron Lazar, Celebrated TV and film actor and Broadway star who has become a powerful new advocate in the fight against ALS following his recent diagnosis.</description>
</item>
</channel>
</rss>